Compositions and methods for reducing cancer stem cells
AssigneeThe Regents of the University of Colorado, a body corporate
InventorsCraig Jordan, Clayton Smith, Courtney L. Jones, Brett Stevens
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions and methods for reducing cancer stem cells. In some aspects, the compositions and methods can comprise at least one metabolism modulating agent. In other aspects, the compositions and methods can comprise at least two metabolism modulating agents.
Claims20
A combination for treating acute myeloid leukemia (AML) in a patient in need thereof, the combination comprising venetoclax and etomoxir.
A combination for treating myelodysplastic syndrome (MDS) in a patient in need thereof, the combination comprising venetoclax and omacetaxine mepesuccinate.
The combination of 8, wherein the combination is administered to the patient in an amount sufficient to induce cell death in MDS stem cells in the patient.
A method for treating MDS in a patient in need thereof comprising administering to the patient a combination of venetoclax, azacitidine, and omacetaxine mepesuccinate.
A method for treating AML in a patient with relapsed AML in need thereof comprising administering to the patient a combination of veneticlax and azacitidine.
A method for treating AML in a patient in need thereof comprising administering a combination of venetoclax and azacitidine to the patient in need thereof, wherein a sample from the patient was genotyped and identified as having a mutation in isocitrate dehydrogenase (IDH) isoform 1 or 2.
Dependencies are inferred from the claim text.